New York (December 19th, 2012) - Peregrine Pharmaceuticals (NASDAQ: PPHM) 1.25, -0.03, (-2.34%).Peregrine’s third’s consecutive quarter in which Peregrine's red ink is narrowing at a quicker pace than Wall Street analyst are expecting. Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer.
The Company's pipeline of investigational monoclonal antibodies is based on two technology platforms, including PS-targeting antibodies and DNA/histone-targeting antibodies. Bavituximab is the Company's therapeutic PS-targeting antibody, which has demonstrated therapeutic potential and represents a new approach to treating cancer. The biotech’s potentially promising treatment for non-small-cell lung cancer.
Find out where PPHM could be headed by getting the free full report here:
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) 4.83 -0.04 (-0.82%). Acadia Pharmaceuticals is raising an expected $86.4 million from a private placement of company stock. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.
The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831.
Find out what traders need to do in the very short with ACAD by getting the free full report here: http://www.wallstreetreport.net/market-scan/?symbol=ACAD About Us: WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership. Simply sign up for free and start receiving exclusive alerts. Subscribe Here: http://www.WallStreetReport.net Disclosure: WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures. Contact Info: Michael BaineWALL STREET REPORTinfo@WallStreetReport.net347-905-5009